Talk:Multiple myeloma: Difference between revisions

Content deleted Content added

Inline

Revision as of 02:15, 28 January 2018

This is the talk page for discussing improvements to the Multiple myeloma article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1: 12 months

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Multiple myeloma.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Medicine: Hematology-oncology B‑class Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
B	This article has been rated as B-class on Wikipedia's content assessment scale.
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Hematology-oncology task force.

Veterinary medicine Start‑class Mid‑importance

	This article is within the scope of WikiProject Veterinary medicine, a collaborative effort to improve the coverage of Veterinary medicine on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Veterinary medicineWikipedia:WikiProject Veterinary medicineTemplate:WikiProject Veterinary medicineVeterinary medicine
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Mid	This article has been rated as Mid-importance on the project's importance scale.

Archives

Archive 1

This page has archives. Sections older than 365 days may be automatically archived by when more than 4 sections are present.

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

Cglife.trummler (talk · contribs) has been paid by CG Life on behalf of Impact Journals.

.

Reviews

Numerous translational reviews in Blood this week: http://bloodjournal.org/content/125/20 - 15 May 2015‎

Refractory and relapsed disease

Network meta-analysis doi:10.1182/bloodadvances.2016003905 JFW | T@lk 20:28, 13 March 2017 (UTC)[reply]

Relapse

Proposed edit: Following the sentence "Bortezomib is a proteasome inhibitor," add, "Identifying the levels of specific proteins may help doctors identify whether a patient will benefit from a proteasome inhibitor." Citation: doi:10.18632/oncoscience.356

I'd like to open this to discussion because the citation is primary research, so not ideal. However, the first sentence does not give readers any context as the significance of being a proteasome inhibitor or how physicians use that information. The purpose of this edit would be to help fill that gap. Thoughts? Cglife.trummler (talk) 22:43, 14 November 2017 (UTC)[reply]

I'm sure there are better sources that are more compliant with WP:MEDRS. I find a fair number when searching Pubmed with "proteasome inhibitors" as MAJR term. JFW | T@lk 23:01, 14 November 2017 (UTC)[reply]

No. We call this WP:REFSPAM. Please stop doing this. Thanks. Jytdog (talk) 06:13, 15 November 2017 (UTC)[reply]

Updating and expanding prognosis info

Two points:

1. The Prognosis section states "Overall the 5-year survival rate is around 35%". The source for this (63) states "Archived from the original on 11 January 2013." However, following the source link given leads to an article that notes at the top it has been updated on Jan 11, 2018. In that article, under the heading Prognosis it says "The 5-year relative survival rate is 46.6%." I am not expert enough to know if "overall" and "relative" have different meanings in this context, but it appears to me as if the survival rate has improved since the original source was written. Should this be updated?

2. The same source (https://emedicine.medscape.com/article/204369-overview#showall) also gives information on the difference in prognosis due to type of treatment:

The prognosis by treatment is as follows:
• Conventional therapy: Overall survival is approximately 3 years, and event-free survival is less than 2 years.
• High-dose chemotherapy with stem-cell transplantation: The overall survival rate is greater than 50% at 5 years.

This might be good information to include.

Grindle2095 (talk) 13:41, 27 January 2018 (UTC)[reply]

Medscape isn't an ideal source. I agree that there must be a more recent MEDRS-compatible source present somewhere. JFW | T@lk 22:49, 27 January 2018 (UTC)[reply]

@@ Line 18: / Line 18: @@
 Numerous translational reviews in ''Blood'' this week: http://bloodjournal.org/content/125/20 - 15 May 2015‎
-== BCSH ==
-Late and long term complications of myeloma and its treatment: guideline [[doi:10.1111/bjh.14514]] [[User:Jfdwolff|JFW]]&nbsp;&#124;&nbsp;[[User_talk:Jfdwolff|<small>T@lk</small>]] 12:05, 24 January 2017 (UTC)
 == Refractory and relapsed disease ==